These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 37717608)

  • 1. Comparing minimum inhibitory concentrations of amikacin for pulmonary Mycobacterium avium complex disease: An analysis of culture media differences.
    Morita A; Namkoong H; Uwamino Y; Mitarai S; Aono A; Asakura T; Yagi K; Tanaka H; Azekawa S; Nakagawara K; Kaji M; Nagao G; Kamata H; Matsushita H; Fukunaga K; Hasegawa N
    J Infect Chemother; 2024 Feb; 30(2):159-163. PubMed ID: 37717608
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by
    Griffith DE; Eagle G; Thomson R; Aksamit TR; Hasegawa N; Morimoto K; Addrizzo-Harris DJ; O'Donnell AE; Marras TK; Flume PA; Loebinger MR; Morgan L; Codecasa LR; Hill AT; Ruoss SJ; Yim JJ; Ringshausen FC; Field SK; Philley JV; Wallace RJ; van Ingen J; Coulter C; Nezamis J; Winthrop KL;
    Am J Respir Crit Care Med; 2018 Dec; 198(12):1559-1569. PubMed ID: 30216086
    [No Abstract]   [Full Text] [Related]  

  • 3. In vitro activity of amikacin against isolates of Mycobacterium avium complex with proposed MIC breakpoints and finding of a 16S rRNA gene mutation in treated isolates.
    Brown-Elliott BA; Iakhiaeva E; Griffith DE; Woods GL; Stout JE; Wolfe CR; Turenne CY; Wallace RJ
    J Clin Microbiol; 2013 Oct; 51(10):3389-94. PubMed ID: 23946523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amikacin Liposome Inhalation Suspension: A Review in Mycobacterium avium Complex Lung Disease.
    Shirley M
    Drugs; 2019 Apr; 79(5):555-562. PubMed ID: 30877642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amikacin Liposome Inhalation Suspension for
    Golia A; Mahmood BR; Fundora Y; Thornby KA; Chahine EB
    Sr Care Pharm; 2020 Apr; 35(4):162-170. PubMed ID: 32192565
    [No Abstract]   [Full Text] [Related]  

  • 6. Amikacin Liposome Inhalation Suspension for
    Winthrop KL; Flume PA; Thomson R; Mange KC; Yuen DW; Ciesielska M; Morimoto K; Ruoss SJ; Codecasa LR; Yim JJ; Marras TK; van Ingen J; Wallace RJ; Brown-Elliott BA; Coulter C; Griffith DE
    Ann Am Thorac Soc; 2021 Jul; 18(7):1147-1157. PubMed ID: 33326356
    [No Abstract]   [Full Text] [Related]  

  • 7. Rational Choice of Antibiotics and Media for
    Jaffré J; Aubry A; Maitre T; Morel F; Brossier F; Robert J; Sougakoff W; Veziris N;
    Front Microbiol; 2020; 11():81. PubMed ID: 32140138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amikacin Liposome Inhalation Suspension for Refractory Mycobacterium avium Complex Lung Disease: Sustainability and Durability of Culture Conversion and Safety of Long-term Exposure.
    Griffith DE; Thomson R; Flume PA; Aksamit TR; Field SK; Addrizzo-Harris DJ; Morimoto K; Hoefsloot W; Mange KC; Yuen DW; Ciesielska M; Wallace RJ; van Ingen J; Brown-Elliott BA; Coulter C; Winthrop KL;
    Chest; 2021 Sep; 160(3):831-842. PubMed ID: 33887244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Towards clinical breakpoints for non-tuberculous mycobacteria - Determination of epidemiological cut off values for the Mycobacterium avium complex and Mycobacterium abscessus using broth microdilution.
    Fröberg G; Maurer FP; Chryssanthou E; Fernström L; Benmansour H; Boarbi S; Mengshoel AT; Keller PM; Viveiros M; Machado D; Fitzgibbon MM; Mok S; Werngren J; Cirillo DM; Alcaide F; Hyyryläinen HL; Aubry A; Andres S; Nadarajan D; Svensson E; Turnidge J; Giske CG; Kahlmeter G; Cambau E; van Ingen J; Schön T;
    Clin Microbiol Infect; 2023 Jun; 29(6):758-764. PubMed ID: 36813087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Difference in drug susceptibility distribution and clinical characteristics between
    Wang W; Yang J; Wu X; Wan B; Wang H; Yu F; Guo Y
    J Med Microbiol; 2021 May; 70(5):. PubMed ID: 33999797
    [No Abstract]   [Full Text] [Related]  

  • 11. Evaluating amikacin minimum inhibitory concentration in trailing growth for Mycobacterium avium complex.
    Park B; Shim TS; Jo KW; Won EJ; Kim MN; Sung H
    Tuberculosis (Edinb); 2023 Dec; 143():102427. PubMed ID: 37918057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amikacin liposome inhalation suspension as a treatment for patients with refractory mycobacterium avium complex lung infection.
    Zhang Y; Hill AT
    Expert Rev Respir Med; 2021 Jun; 15(6):737-744. PubMed ID: 34039231
    [No Abstract]   [Full Text] [Related]  

  • 13. Amikacin liposome inhalation suspension for Mycobacterium avium complex pulmonary disease: A subgroup analysis of Japanese patients in the randomized, phase 3, CONVERT study.
    Morimoto K; Nonaka M; Yamazaki Y; Nakagawa T; Takasaki J; Tsuyuguchi K; Kitada S; Jumadilova Z; Yuen DW; Ciesielska M; Hasegawa N
    Respir Investig; 2024 Mar; 62(2):284-290. PubMed ID: 38277865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antimicrobial susceptibility and minimum inhibitory concentration distribution of common clinically relevant non-tuberculous mycobacterial isolates from the respiratory tract.
    He G; Wu L; Zheng Q; Jiang X
    Ann Med; 2022 Dec; 54(1):2500-2510. PubMed ID: 36120867
    [No Abstract]   [Full Text] [Related]  

  • 15. Amikacin Liposome Inhalation Suspension in Refractory Mycobacterium avium Complex Lung Disease: A Profile of Its Use.
    Hoy SM
    Clin Drug Investig; 2021 Apr; 41(4):405-412. PubMed ID: 33723805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A case of drug-induced organizing pneumonia caused by amikacin liposome inhalation suspension.
    Takao D; Takeda K; Takazono T; Ozasa M; Ito Y; Ashizawa N; Hirayama T; Iwanaga N; Takemoto S; Ide S; Tashiro M; Hosogaya N; Kido T; Sakamoto N; Obase Y; Okano S; Izumikawa K; Yanagihara K; Mukae H
    J Infect Chemother; 2023 Aug; 29(8):806-808. PubMed ID: 37098378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population Pharmacokinetic Evaluation of Amikacin Liposome Inhalation Suspension in Patients with Treatment-Refractory Nontuberculous Mycobacterial Lung Disease.
    Rubino CM; Onufrak NJ; van Ingen J; Griffith DE; Bhavnani SM; Yuen DW; Mange KC; Winthrop KL
    Eur J Drug Metab Pharmacokinet; 2021 Mar; 46(2):277-287. PubMed ID: 33595792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Use of Amikacin Liposome Inhalation Suspension (Arikayce) in the Treatment of Refractory Nontuberculous Mycobacterial Lung Disease in Adults.
    Khan O; Chaudary N
    Drug Des Devel Ther; 2020; 14():2287-2294. PubMed ID: 32606598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GenoType NTM-DR Performance Evaluation for Identification of Mycobacterium avium Complex and Mycobacterium abscessus and Determination of Clarithromycin and Amikacin Resistance.
    Huh HJ; Kim SY; Shim HJ; Kim DH; Yoo IY; Kang OK; Ki CS; Shin SY; Jhun BW; Shin SJ; Daley CL; Koh WJ; Lee NY
    J Clin Microbiol; 2019 Aug; 57(8):. PubMed ID: 31167842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amikacin Inhalation as Salvage Therapy for Refractory Nontuberculous Mycobacterial Lung Disease.
    Jhun BW; Yang B; Moon SM; Lee H; Park HY; Jeon K; Kwon OJ; Ahn J; Moon IJ; Shin SJ; Daley CL; Koh WJ
    Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29661870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.